Loading...
Loading...
TSHA| Name | Value |
|---|---|
| Revenues | 3.6M |
| Cost of Revenue | 0.4M |
| Gross Profit | 3.2M |
| Operating Expense | 19.0M |
| Operating I/L | -15.8M |
| Other Income/Expense | 64.0M |
| Interest Income | 1.9M |
| Pretax | 47.7M |
| Income Tax Expense | -3.5M |
| Net Income/Loss | 47.7M |
Taysha Gene Therapies, Inc. is a gene therapy company specializing in adeno-associated virus-based gene therapies for monogenic diseases of the central nervous system. Its product portfolio includes TSHA-120 for giant axonal neuropathy, TSHA-102 for Rett syndrome, TSHA-121 and TSHA-118 for CLN1 disease, TSHA-105 for SLC13A5 Deficiency, and TSHA-101 for GM2 gangliosidosis. The company generates revenue through the development and commercialization of these transformative gene therapy treatments, with a strategic partnership with The University of Texas Southwestern Medical Center to further its research and development efforts.
